viekirax
abbvie deutschland gmbh co. kg - ombitasvir, paritaprevir, rítónavír - lifrarbólga c, langvinn - veirueyðandi lyf til almennrar notkunar - viekirax er ætlað í samsettri meðferð með öðrum lyfjum til meðferðar við langvarandi lifrarbólgu c (chc) hjá fullorðnum. fyrir lifrarbólgu c veira (hcv) arfgerð ákveðna virkni.
kymriah
novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - Önnur æxlishemjandi lyf - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.
dailiport hart forðahylki 5 mg
sandoz a/s - tacrolimus monohydrate; tacrolimus - hart forðahylki - 5 mg
certican tafla 0,75 mg
novartis healthcare a/s - everolimusum inn - tafla - 0,75 mg
octaplex innrennslisstofn og leysir, lausn 1000 a.e.
octapharma ab - factor ii human; factor vii human; factor ix human; factor x human; protein c; protein s - innrennslisstofn og leysir, lausn - 1000 a.e.
certican tafla 0,5 mg
novartis healthcare a/s - everolimusum inn - tafla - 0,5 mg
certican tafla 0,25 mg
novartis healthcare a/s - everolimusum inn - tafla - 0,25 mg
dailiport hart forðahylki 0,5 mg
sandoz a/s - tacrolimus monohydrate; tacrolimus - hart forðahylki - 0,5 mg
dailiport hart forðahylki 1 mg
sandoz a/s - tacrolimus monohydrate; tacrolimus - hart forðahylki - 1 mg
dailiport hart forðahylki 2 mg
sandoz a/s - tacrolimus; tacrolimus monohydrate - hart forðahylki - 2 mg